Introduction: In 2019, the PD-L1 inhibitor atezolizumab became the first immune checkpoint inhibitor approved for treatment in patients with breast cancer. The approval is restricted to patients with metastatic triple-negative breast cancer (TNBC) whose tumors are PD-L1 positive. There is a ...
In the phase 2 KEYLYNK-009 trial, investigators tested the efficacy and safety of maintenance therapy with pembrolizumab and olaparib vs pembrolizumab with chemotherapy in patients with locally recurrent inoperable or metastatic TNBC who had clinical benefit from induction frontline pembrolizu...
Locally recurrent unresectable or metastatic TNBC Indicated, in combination with chemotherapy, for locally recurrent unresectable or metastatic triple-negative breast cancer (TNBC) whose tumors express PD-L1 (CPS 10 or higher) 200 mg IV every 3 weeks OR 400 mg every 6 weeks Continue until disease...
In KEYNOTE-355, when KEYTRUDA and chemotherapy (paclitaxel, paclitaxel protein-bound, or gemcitabine and carboplatin) were administered to patients with locally recurrent unresectable or metastatic TNBC who had not been pre...
"The combination of eribulin plus pembrolizumab demonstrated activity in patients with metastatic TNBC. Objective responses, including a complete response, were observed during this interim analysis," Sara M. Tolaney, MD, MPH, from the Dana-Farber Cancer Institute, and colleagues wrote in their poste...
Moreover, in patients with T2N0 tumors, the EFS rates with pembrolizumab vs placebo were 87.8% vs 77.9%, respectively (HR, 0.49; 95% CI, 0.31-0.78). This finding demonstrates that patients with small cancers have significantly improved outcomes when they receive pembrolizumab as part of their...
In KEYNOTE-355, when KEYTRUDA (pembrolizumab) and chemotherapy (paclitaxel, paclitaxel protein-bound, or gemcitabine and carboplatin) were administered to patients with locally recurrent unresectable or metastatic TNBC who h...
In KEYNOTE-355, when KEYTRUDA and chemotherapy (paclitaxel, paclitaxel protein-bound, or gemcitabine and carboplatin) were administered to patients with locally recurrent unresectable or metastatic TNBC who had not been previously treated with chemotherapy in the metastatic setting (n=596), fatal advers...
Officials with the FDA have approved pembrolizumab (Keytruda; Merck), an anti-PD-1 therapy, in combination with chemotherapy for the treatment of patients with locally recurrent unresectable or metastatic triple-negative breast cancer (TNBC) whose tumors express PD-L1 (Combined Positive Score [CPS]...
Methods: Women aged ≥18 y with locally advanced, nonmetastatic TNBC; ECOG PS 0/1; and no prior chemo, targeted therapy, or immunotherapy within 12 mo were eligible. Dosing in A was single-dose pembro followed by 4 cycles of pembro Q3W + nab-paclitaxel (Np) weekly followed by 4 cycles...